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Tail suspension testDuloxetine is a selective serotonin and noradrenaline reuptake inhibitor used as antidepressant. However, its
mechanisms of action are not fully understood. This study investigated the effect of duloxetine in themouse forced
swimming test (FST) and in the tail suspension test (TST) and the involvement of the NMDA receptors and the
L-arginine–NO–cGMP pathway in its effect in the FST. Duloxetine reduced the immobility time both in the FST
and in the TST (dose range of 1–30 mg/kg, i.p.), without changing locomotion in an open-ﬁeld. Duloxetine admin-
istered orally (1–30 mg/kg) also reduced the immobility time in the FST. The effect of duloxetine (10 mg/kg, p.o.)
in the FSTwas prevented by pre-treatmentwithNMDA (0.1 pmol/site, i.c.v.), D-serine (30 μg/site, i.c.v.), (L-arginine
(750 mg/kg, i.p.), S-nitroso-N-acetyl-penicillamine (SNAP, 25 μg/site, i.c.v) or sildenaﬁl (5 mg/kg, i.p.). The admin-
istration of MK-801 (0.001 mg/kg, i.p.), 7-nitroindazole (50 mg/kg, i.p.), methylene blue (20 mg/kg, i.p.) or
1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ) (30 pmol/site i.c.v.) in combination with a sub-effective dose
of duloxetine (0.3 mg/kg, p.o.) reduced the immobility time in the FST. Moreover, the administration of duloxetine
(10 mg/kg) produced a reduction in NOx levels in the hippocampus and cerebral cortex. Altogether the results sug-
gest that the effect of duloxetine in the FST is dependent on either a blockade of NMDA receptors or an inhibition of
NO. In addition, our results further reinforce the role of NMDA receptors and L-arginine–NO–cGMP pathway, be-
sides the monoaminergic systems, in the mechanism of action of current prescribed antidepressant agents.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Depression is a disorder that has a high lifetime prevalence
(around 16%) and is often manifested with symptoms at the psycho-
logical, behavioral and physiological levels. Suicide is usually a conse-
quence of depression and other deleterious health-related effects
have been reported (Wong and Licinio, 2001). Despite the devastat-
ing impact of depression, its etiology or pathophysiology is not well
established. The monoaminergic systems (serotonergic, noradrener-
gic and dopaminergic) have received a great attention in neurobio-
logical studies of depression (Wong and Licinio, 2001). Some
clinical reports suggest that the combination of selective serotonin
(5-HT) reuptake inhibitors with selective noradrenaline (NE) reup-
take inhibitors may present a therapeutic advantage, resulting in a
more effective or rapid antidepressant effect in comparison to each
drug given alone (Shelton et al., 2005; Thase et al., 2007).
Duloxetine is a drug that inhibits 5-HT and NE reuptake, with
weak effects on dopamine reuptake (Hunziker et al., 2005). It isica, CCB, Universidade Federal
anópolis 88040‐900, SC, Brazil.
igues).
vier OA license.used in the treatment of depression (Detke et al., 2004), anxiety
(Carter and McCormack, 2009) and pain (Bellingham and Peng,
2010). It has been proposed that 5-HT and NE reuptake inhibitors
may result in higher remission rates of major depressive disorder
than therapy with selective inhibitors of 5-HT reuptake (Shelton et
al., 2005; Thase et al., 2001; Smith et al., 2002). It has been reported
that duloxetine has some advantages over other antidepressants,
since it has greater effectiveness than ﬂuoxetine and paroxetine in
patients with moderate to severe depression (Thase et al., 2007)
and has a better tolerability than venlafaxine (Stahl et al., 2005).
Moreover, it is generally well tolerated and has fewer adverse effects
such as dry mouth, nausea, fatigue (Hunziker et al., 2005), sexual dys-
function (Stahl et al., 2005) and little or no effect on the cardiovascu-
lar system (Stahl et al., 2005; Hunziker et al., 2005). Of note,
duloxetine-treated patients demonstrated clinically meaningful im-
provements within the ﬁrst weeks of treatment (Brannan et al.,
2005). Regarding preclinical studies, it was shown that duloxetine re-
duced the immobility time in the forced swimming test (FST) in rats
(Ciulla et al., 2007; Rénéric and Lucki, 1998).
Several clinical studies have demonstrated abnormalities in gluta-
mate function inmood disorders. Some studies have indicated that com-
pounds that reduce transmission at N-methyl-D-aspartate (NMDA)
receptors and NMDA receptor antagonists exhibit antidepressant-like
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pressed patients also showed a signiﬁcant improvement after the
acute administration of ketamine, a non-competitive NMDA receptor
antagonist (Berman et al., 2000; Zarate et al., 2006). Moreover, it is
also noteworthy that NMDA receptor antagonists exert synergistic
antidepressant-like effects with classical antidepressants in the FST
(Rogóz et al., 2002). Also, the use of MK801, a non-competitive NMDA
antagonist, during imipramine withdrawal following chronic imipra-
mine treatment resulted in signiﬁcant suppression of swim stress
immobility (Harvey et al., 2002).
The NMDA receptor stimulation induces the activation of nitric oxide
(NO) synthase (NOS). The activated NOS then converts L-arginine to NO
and L-citrulline (Esplugues, 2002). NO is a signalingmolecule in the brain
and has been implicated in depression (Da Silva et al., 2000;
Harkin et al., 1999, 2004; Heiberg et al., 2002). It has been demon-
strated that the reduction of NO levels within the hippocampus
can induce antidepressant-like effects, thus implicating endoge-
nous hippocampal NO in the neurobiology of depression (Joca
and Guimarães, 2006). In addition, plasma nitrate concentrations
were signiﬁcantly increased in depressed patients, suggesting
that NO production is enhanced in depression (Suzuki et al.,
2001). Several studies have demonstrated that NOS inhibitors,
depending on their concentration, exert antidepressant-like ef-
fects (Da Silva et al., 2000; Harkin et al., 2003, 2004; Volke et al.,
2003). Some of the physiological actions of NO are mediated
through the enzyme guanylate cyclase (sGC) with the consequent
increase in cyclic guanosine monophosphate (cGMP) levels. It is
currently accepted that the NO–cGMP pathway is the main effec-
tor of NO actions in the brain (Esplugues, 2002).
Although the behavioral studies using duloxetine in the FST sup-
port its antidepressant properties (Ciulla et al., 2007; Rénéric and
Lucki, 1998), its mechanisms of action besides the monoaminergic
system are not fully understood. The present study examined wheth-
er duloxetine produces antidepressant-like effect in the FST and also
in another model predictive of antidepressant activity, the TST, in
mice. These behavioral tests have good predictive value for antide-
pressant potency in man (Cryan et al., 2002). Considering that the
blockade of NMDA receptor is associated with reduced levels of NO
and cGMP (Snyder, 1992) and the inhibition of both NOS and sGC
may, depending on the dose, elicit antidepressant-like effects in the
FST (Eroglu and Caglayan, 1997; Da Silva et al., 2000; Harkin et al.,
2003; Heiberg et al., 2002; Volke et al., 2003; Yildiz et al., 2000), we
investigated whether NMDA receptors and L-arginine–NO–cGMP
pathway may be involved in the effect of acute duloxetine adminis-
tration in mouse FST.
2. Materials and methods
2.1. Animals
Swiss albino femalemice (30–40 g, 55–70 days old)weremaintained
at 21–23 °Cwith free access towater and food, under a 12:12 h light/dark
cycle (lights on at 7:00 h). Animals were obtained from the Central
Biothery of Universidade Federal de Santa Catarina (UFSC). All manipula-
tionswere carried out between9:00 a.m. and4:00 p.m.,with each animal
used only once. All procedures in this study were performed in accor-
dance with the National Institute of Health Guide for the Care and Use
of Laboratory Animals (NIH Publication No. 80‐23). The experiments
were performed after approval of the protocol by the Institutional Ethics
Committee and all efforts were made to minimize animals' suffering
and to reduce the number of animals used in the experiments.
2.2. Drugs and pharmacological treatments
Duloxetine HCl (Eli Lilly & Co.), L-arginine, methylene blue,
N-methyl-D-aspartate (NMDA), 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ), 7-nitroindazole and D-serine (Sigma Chemical Co, USA),
S-nitroso-N-acetyl-penicillamine (SNAP), sildenaﬁl (Pﬁzer) and MK-
801 (Research Biochemicals International, USA) were used. All drugs
were dissolved in saline, except ODQ which was dissolved in saline
with 1% dimethylsulfoxide (DMSO) and 7-nitroindazole that was
dissolved in 5% Tween 80. All drugs were administered by intraperitone-
al (i.p.) route in a constant volume of 10 ml/kg body weight, except
NMDA, D-serine, ODQ and SNAP which were administered by intra-
cerebroventricular (i.c.v.) route (5 μl/site).
I.c.v. administration was performed under ether anesthesia as
previously described (Brocardo et al., 2008). Brieﬂy, mice were
placed inside a glass jar containing ether. The animals remained in-
side the glass jar for 30 s and immediately after, the i.c.v. administra-
tion was performed. Brieﬂy, a 0.4 mm external diameter hypodermic
needle attached to a cannula, which was linked to a 25 μl Hamilton
syringe, was inserted perpendicularly through the skull and no
more than 2 mm into the brain of the mouse. A volume of 5 μl was
then administered in the left lateral ventricle. The injection was
given over 30 s, and the needle remained in place for another 30 s
in order to avoid the reﬂux of the substances injected. To ascertain
that the drugs were administered exactly into the cerebral ventricle,
the brains were dissected and examined macroscopically after the
test.
Duloxetine was also administered by oral (p.o.) route by gavage in
a volume of 10 ml/kg body weight.
In order to investigate the antidepressant-like effect of the duloxetine,
it was administered (dose range: 0.3–30 mg/kg, i.p.) 30 min before the
FST, TST or open-ﬁeld test. Alternatively, duloxetine or vehicle was ad-
ministered by oral (p.o.) route (dose range: 0.3–30 mg/kg, p.o.) 60 min
before the FST or open-ﬁeld test.
In a separate series of experiments, we investigated whether the
antidepressant-like effect of duloxetine in the FST is mediated
through the blockade of NMDA receptors. To this end, mice were
pretreated with NMDA (0.1 pmol/site, i.c.v.) or with D-serine
(30 μg/site, i.c.v., a coagonist at the NMDA receptor) and 15 min
after, duloxetine (10 mg/kg, p.o.) or vehicle was administered. Sixty
minutes later the FST was carried out.
In another set of experiments, we investigated the synergistic
effect of a sub-effective dose of duloxetine (0.3 mg/kg, p.o.) with a
sub-effective dose of MK-801 (0.001 mg/kg, i.p., a non-competitive
NMDA receptor antagonist). Duloxetine or vehicle was administered
30 min before MK-801. A further 30 min was allowed to elapse
before the animals were tested in the FST.
To investigate the possible involvement of the L-arginine–nitric
oxide pathway in the anti-immobility effects of duloxetine in the
FST, in an experimental protocol aimed at increasing NO levels, mice
were pre-treated with L-arginine, a precursor of NO (750 mg/kg, i.p.,
a dose that produces no effect in the FST) or with the NO donor
SNAP (25 μg/site, i.c.v., a dose that produces no effect in the FST) or
vehicle. Thirty minutes after L-arginine or 15 min after SNAP admin-
istration, duloxetine (10 mg/kg, p.o.) or vehicle was injected, and
60 min later the FST was carried out.
In another set of experiments, we investigated the effect of
the combined administration of a sub-effective dose of duloxetine
(0.3 mg/kg, p.o.) with sub-effective doses of 7-nitroindazole
(50 mg/kg, i.p., a speciﬁc neuronal NOS inhibitor), ODQ (30 pmol/
site i.c.v., a speciﬁc sGC inhibitor) or methylene blue (20 mg/kg,
i.p., an inhibitor of both NOS and sGC). Duloxetine or vehicle was
administered 30 min before of 7-nitroindazole, methylene blue
or 40 min before ODQ. A further 30 min (after i.p. administration of
7-nitroindazole or methylene blue) or 20 min (after i.c.v. ODQ
administration) was allowed to elapse before the animals were tested
in the FST.
In order to investigate the role of cGMP in the antidepressant
action of duloxetine, in an experimental protocol aimed at increasing
cGMP levels, mice received an injection of sildenaﬁl (5 mg/kg, i.p., a
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(10 mg/kg, p.o.) and 60 min later the FST was carried out.
The doses of the drugs used were selected on the basis of literature
data and on previous results from our laboratory (Almeida et al.,
2006; Brocardo et al., 2008; Da Silva et al., 2000; Dhir and Kulkarni,
2007; Kaster et al., 2005a,2005b; Rosa et al., 2003; Zomkowski et al.,
2010). The doses of duloxetine administered were chosen on the
basis of experiments previously performed in our laboratory and lit-
erature data (Bomholt et al., 2005; Rénéric and Lucki, 1998).
In order to evaluate a putative effect of duloxetine on NO levels, an
indirect measurement of NO levels via the production of nitrite formed
from its metabolism, was performed. Animals received distilled water
or duloxetine (10 mg/kg, p.o.). After 60 min, animals were killed by de-
capitation and hippocampi and cerebral cortices were rapidly removed.
Brieﬂy, one cerebral cortex or a pool of three hippocampi were mixed
with 25% trichoroacetic and centrifuged at 1800 g for 10 min. The
supernatant was immediately neutralized with 2 M potassium bicar-
bonate. Nitrate (NO3−)was reduced to nitrite (NO2−) bynitrate reduc-
tase. The total NO2− in the incubation was measured by a colorimetric
assay read at 540 nm, based on the Griess reaction. A standard curve
was performed using sodium nitrate (0–80 μΜ). Results were ex-
pressed as % of control (100%) (Hevel and Marletta, 1994).2.3. Behavioral tests
2.3.1. Forced swimming test
The FST was conducted using the method of Porsolt et al. (1977)
with some modiﬁcations. Mice were individually forced to swim in
an open cylindrical container (diameter 10 cm, height 25 cm),
containing 19 cm of water at 25±1 °C; the total duration of immo-
bility during the 6-min test was scored as described previously
(Brocardo et al., 2008). Each mouse was judged to be immobile
when it ceased struggling and remained ﬂoating motionless in the
water, making only those movements necessary to keep its head
above water.2.3.2. Tail suspension test
The total duration of immobility induced by tail suspension was
measured according to the method described by Steru et al. (1985).
Brieﬂy, mice both acoustically and visually isolated were suspended
50 cm above the ﬂoor by adhesive tape placed approximately 1 cm
from the tip of the tail. Immobility time was recorded during a
6 min period (Binfaré et al., 2009).2.3.3. Open-ﬁeld behavior
The ambulatory behavior was assessed in an open-ﬁeld test as de-
scribed previously (Brocardo et al., 2008). The apparatus consisted of
a wooden box measuring 40×60×50 cm high. The ﬂoor of the arena
was divided into 12 equal squares. The number of squares crossed
with all paws (crossings) was counted in a 6-min session. The light
was maintained at minimum to avoid anxiety behavior. The appara-
tus was cleanedwith a solution of 10% ethanol between tests in order
to hide animal cues.2.4. Statistical analysis
Comparisons between treatment groups and control were per-
formed by one-way (dose–response experiments) or two-way (experi-
ments dealing with the role of NMDA receptors and L-arginine–NO–
cGMP pathway in the antidepressant effect of duloxetine) analysis of
variance (ANOVA) followed by Tukey's HSD test when appropriate. A
value of pb0.05 was considered to be signiﬁcant.3. Results
3.1. Effect of duloxetine in the immobility time in the FST and TST and on
the locomotor activity in the open-ﬁeld test
The treatment ofmicewith duloxetine at thedose range 1–30 mg/kg
given by intraperitoneal route signiﬁcantly decreased the immobility
time both in the FST [F(5,44)=83.01, pb0.01; Fig. 1A] and in the TST
[F(5,30)=70.47, pb0.01; Fig. 1B]. The doses of duloxetine that
produced an anti-immobility effect in the FST and TST (1–30 mg/kg)
did not cause any change in ambulation in an open-ﬁeld in a separate
experiment as compared to the control group [F(5,32)=1.56, p=
0.20; Fig. 1C]. Fig. 1D shows that duloxetine also caused a reduction in
the immobility time in the FST when administered by p.o. route at the
dose range 1–30 mg/kg [F(5,30)=51.91, pb0.01], but did not produce
any change in ambulation in mice tested in an open-ﬁeld in a separate
experiment [F(5,30)=2.15, p=0.09; Fig. 1E].
3.2. Involvement of NMDA receptors on the antidepressant-like effect of
duloxetine in the FST
Fig. 2A shows that the pre-treatment of mice with NMDA
(0.1 pmol/site, i.c.v.) was able to reverse the antidepressant-like
effect of duloxetine (10 mg/kg, p.o.) in the FST. A two-way ANOVA
revealed signiﬁcant differences for the NMDA pre-treatment [F(1,20)=
102.15, pb0.01], duloxetine treatment [F(1,20)=95.78, pb0.01] and
NMDA×duloxetine interaction [F(1,20)=64.39, pb0.01]. The admin-
istration of NMDA alone or in combinationwith duloxetine did not affect
the ambulation in the open-ﬁeld (Fig. 2B). A two-way ANOVAdid not re-
veal signiﬁcant differences for the NMDA pre-treatment [F(1,20)=1.26,
p=0.27], duloxetine treatment [F(1,20)=2.00, p=0.17] and NMDA×
duloxetine interaction [F(1,20)=0.25, p=0.62]. Fig. 2C shows that
D-serine (30 μg/site, i.c.v.) was able to prevent the reduction in the im-
mobility time elicited by duloxetine (10 mg/kg, p.o.) in the FST. A
two-way ANOVA revealed signiﬁcant differences for D-serine pre-
treatment [F(1,20)=30.60, pb0.01], duloxetine treatment [F(1,20)=
32.29, pb0.01] and D-serine×duloxetine interaction [F(1,20)=37.96,
pb0.01]. The administration of D-serine alone or in combination with
duloxetine did not affect locomotor activity in the open-ﬁeld test. A
two-way ANOVA did not reveal signiﬁcant differences for D-serine pre-
treatment [F(1,20)=0.67, p=0.42], duloxetine treatment [F(1,20)=
0.07, p=0.80] and D-serine×duloxetine interaction [F(1,20)=3.50,
p=0.08] (Fig. 2D). The results illustrated in Fig. 2E show that the admin-
istration of MK-801 (0.001 mg/kg, i.p., non-competitive NMDA receptor
antagonist) in combination with duloxetine (0.3 mg/kg, p.o.) produced
an antidepressant-like effect as compared with the administration of
either drug alone. A two-way ANOVA revealed signiﬁcant differences
for the duloxetine pre-treatment [F(1,20)=23.62, pb0.01], MK-801
treatment [F(1,20)=31.62, pb0.01] and duloxetine×MK-801 interac-
tion [F(1,20)=12.48, pb0.01]. Fig. 2F shows that the administration of
MK-801 alone or in combination with duloxetine did not affect
locomotion in the open-ﬁeld test. A two-way ANOVA did not reveal
signiﬁcant differences for the duloxetine pre-treatment [F(1,20)=3.72,
p=0.07], MK-801 treatment [F(1,20)=1.18, p=0.29] and duloxetine×
MK-801 interaction [F(1,20)=0.35, p=0.56].
3.3. Involvement of L-arginine–NO–cGMP pathway in the anti-immobility
effect of duloxetine in the FST
The results depicted in Fig. 3A show that pre-treatment with
L-arginine (750 mg/kg i.p., an NO precursor) prevented the
antidepressant-like effect of duloxetine (10 mg/kg, p.o.) in the FST. The
two-way ANOVA showed signiﬁcant differences for L-arginine pre-
treatment [F(1,20)=22.13, pb0.01], duloxetine treatment [F(1,20)=
43.96, pb0.01] and L-arginine×duloxetine interaction [F(1,20)=24.75,
pb0.01]. The administration of L-arginine alone or in combination
Fig. 1. Effect of intraperitoneal administration of duloxetine (0.3–30 mg/kg) in the immobility time in the FST (A), TST (B) and on the number of crossings in the open-ﬁeld test (C) and the
effect of oral administration of duloxetine (0.3–30 mg/kg) in the immobility time in the FST (D) and on the number of crossings in the open-ﬁeld test (E) inmice. Values are expressed as
mean±SEM. Values are expressed as mean±SEM, n=6–11. **Pb0.01 compared with the vehicle-treated control group.
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(Fig. 3B). A two-way ANOVA did not reveal signiﬁcant differences
for the L-arginine pre-treatment [F(1,20)=1.29, p=0.27], duloxetine
treatment [F(1,20)=0.08, p=0.77] and L-arginine×duloxetine inter-
action [F(1,20)=3.25, p=0.86]. Fig. 3C shows that SNAP (25 μg/site,
i.c.v., a NO donor) was able to prevent the reduction in the immo-
bility time elicited by duloxetine (10 mg/kg, p.o.) in the FST. The two-
way ANOVA showed signiﬁcant differences for SNAP pre-treatment
[F(1,20)=53.68, pb0.01], duloxetine treatment [F(1,20)=65.99,
pb0.01] and SNAP×duloxetine interaction [F(1,20)=109.42, pb0.01].
The administration of SNAP alone or in combination with duloxetine
did not affect the ambulation in the open-ﬁeld test (Fig. 3D). A two-
way ANOVA did not reveal signiﬁcant differences for SNAP pre-
treatment [F(1,20)=0.79, p=0.38], duloxetine treatment [F(1,20)=
0.55, p=0.47] and SNAP×duloxetine interaction [F(1,20)=0.61,
p=0.44].
The results illustrated in Fig. 4A show the administration of
7-nitroindazole (50 mg/kg i.p., a speciﬁc neuronal neuronal NOS inhibi-
tor) in combination with duloxetine (0.3 mg/kg, p.o.) produced an
antidepressant-like effect as compared with the administration of either
drug alone. A two-way ANOVA revealed signiﬁcant differences for the
duloxetine pre-treatment [F(1,20)=34.36, pb0.01], 7-nitroindazole
treatment [F(1,20)=60.45, pb0.01] and duloxetine×7-nitroindozole in-
teraction [F(1,20)=26.31, pb0.01]. Fig. 4B shows that the administration
of 7-nitroindazole alone or in combination with duloxetine did not affectlocomotor activity in the open-ﬁeld test. A two-way ANOVA did not re-
veal signiﬁcant differences for the duloxetine pre-treatment [F(1,20)=
2.27, p=0.15], 7-nitroindazole treatment [F(1,20)=1.28, p=0.27] and
7-nitroindazole×duloxetine interaction [F(1,20)=0.32, p=0.58].
Fig. 4C shows that methylene blue (20 mg/kg i.p., direct inhibitor of
both NOS and sGC) in combination with duloxetine (0.3 mg/kg, p.o.)
also produced an anti-immobility effect in the FST as compared with
the administration of either drug alone. A two-way ANOVA revealed sig-
niﬁcant differences for the duloxetine pre-treatment [F(1,20)=16.48,
pb0.01], methylene blue treatment [F(1,20)=28.53, pb0.01] and
duloxetine×methylene blue interaction [F(1,20)=10.27, pb0.01]. The
administration of methylene blue (20 mg/kg i.p.) alone or in combina-
tion with duloxetine did not affect the ambulation in the open-ﬁeld
(Fig. 4D). A two-way ANOVA did not reveal signiﬁcant differences for
the duloxetine pre-treatment [F(1,20)=4.02, p=0.06], methylene
blue treatment [F(1,20)=0.86, p=0.36] and duloxetine×methylene
blue interaction [F(1,20)=1.16, P=0.29].
Corroborating the results presented above which suggest that a pu-
tative reduction in NO levels is implicated in the antidepressant-like
effect of duloxetine, Fig. 4E shows that an effective dose of duloxetine
in the FST (10 mg/kg, p.o.) signiﬁcantly reduced the NOx levels in the
hippocampus [F(1,11)=10.42, Pb0.01] and cerebral cortex: [F(1,8)=
7.33, Pb0.05], as compared with the control group (100%).
The results depicted in Fig. 5A show that ODQ (30 pmol/site i.c.v.,
a speciﬁc inhibitor of sGC) in combination with duloxetine (0.3 mg/
Fig. 2. Effect of the pre-treatment of mice with NMDA (0.1 pmol/site, i.c.v.) or D-serine (30 μg/site, i.c.v.) on the anti-immobility action of duloxetine (10 mg/kg, p.o.) in the FST
(panels A and C, respectively) and in the open-ﬁeld test (panels B and D, respectively). Effect of MK-801 (0.001 mg/kg, i.p.) in combination with a sub-effective dose of duloxetine
(0.3 mg/kg, p.o.) in the FST (E) and in the open-ﬁeld test (F). Values are expressed as mean±SEM, n=6. **pb0.01 compared with the vehicle-treated control group; #pb0.01 com-
pared with the same group pretreated with vehicle.
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pared with the administration of either drug alone. A two-way
ANOVA revealed signiﬁcant differences for the duloxetine
pre-treatment [F(1,20)=19.33, pb0.01], ODQ treatment [F(1,20)=
21.47, pb0.01] and duloxetine×ODQ interaction [F(1,20)=15.11,
pb0.01]. The administration of ODQ (30 pmol/site i.c.v.) alone or in
combination with duloxetine did not affect the ambulation in
the open-ﬁeld (Fig. 5B). A two-way ANOVA did not reveal signiﬁcant
differences for the duloxetine pretreatment [F(1,20)=1.20, p=0.28],
ODQ treatment [F(1,20)=0.01, p=0.90] and duloxetine×ODQ interac-
tion [F(1,20)=0.04, p=0.85]. Fig. 5C shows that the anti-immobility
effect of duloxetine (10 mg/kg, p.o.) was completely prevented by pre-
treatment of animals with sildenaﬁl (5 mg/kg, i.p., a phosphodiesterase
5 inhibitor inhibitor). A two-way ANOVA revealed signiﬁcant differences
for the sildenaﬁl pre-treatment [F(1,20)=47.54, pb0.01], duloxetinetreatment [F(1,20)=66.88, pb0.01] and sildenaﬁl×duloxetine inter-
action [F(1,20)=57.44, pb0.01]. The administration of sildenaﬁl
(5 mg/kg, i.p.) alone or in combination with duloxetine did not affect
the locomotor activity in the open-ﬁeld (Fig. 5D). A two-way ANOVA
did not reveal signiﬁcant differences for the sildenaﬁl pre-treatment
[F(1,20)=0.05, p=0.83], duloxetine treatment [F(1,20)=1.72, p=
0.20] and sildenaﬁl×duloxetine interaction [F(1,20)=3.56, p=0.07].
4. Discussion
The FST and the TST are quite sensitive and relatively speciﬁc
for all major classes of antidepressant drugs including tricyclics,
serotonin-speciﬁc reuptake inhibitors, monoamine oxidase inhibi-
tors, and atypicals (Porsolt et al., 1977; Steru et al., 1985).
Fig. 3. Effect of the pre-treatment of mice with L-arginine (750 mg/kg, i.p.) on the anti-immobility action of duloxetine (10 mg/kg, p.o.) in the FST (A) and on the number of cross-
ings in the open-ﬁeld test (B). Effect of the pre-treatment of mice with SNAP (25 μg/site, i.c.v) on the anti-immobility action of duloxetine (10 mg/kg, p.o.) in the FST (C) and on the
number of crossings in the open-ﬁeld test (D). Values are expressed as mean±SEM, n=6. **pb0.01 compared with the vehicle-treated control group; #pb0.01 compared with the
same group pre-treated with vehicle.
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mice in both tests (Porsolt et al., 1977; Steru et al., 1985). The results
presented here show that duloxetine, given systemically (i.p. or p.o.
routes), is effective in producing signiﬁcant antidepressant-like ef-
fects, when assessed in the FST, which is the most widely used tool
for assessing antidepressant activity preclinically (Cryan et al.,
2002). The antidepressant-like action of duloxetine administered i.p.
was conﬁrmed in the TST. This study was performed in female mice,
since several studies have shown that the prevalence of depression
is about two fold higher in women than in men (Wong and Licinio,
2001).
The results indicate that anti-immobility effect of duloxetine is not
associated with any motor effects, since mice treated with duloxetine
did not exhibit increased ambulation when tested in an open-ﬁeld.
This indicates that a psychostimulant effect is not responsible for
the decrease in the immobility elicited in the FST. A number of studies
have demonstrated that several antidepressants administered by i.p.
route produced antidepressant-like effect in the FST in rodents
(Ciulla et al., 2007; Dhir and Kulkarni, 2007; Ghasemi et al., 2009;
Zomkowski et al., 2010). Duloxetine was shown to produce antide-
pressant effect after its administration by the i.p. (40 mg/kg) and sub-
cutaneous routes (10–40 mg/kg) to rats in the FST (Ciulla et al., 2007;
Rénéric and Lucki, 1998, respectively). In the present study, we con-
ﬁrm that duloxetine administered by the i.p. route produces an
antidepressant-like effect in the FST in mice, but at a lower dose–
response range (1–30 mg/kg). In order to further reinforce this anti-
depressant effect, we tested duloxetine in the TST.
Although the FST and TST are widely used for assessing antidepres-
sant activity preclinically, we should take into account that they have
some limitations and their validity as simulations of the psychiatric con-
dition is questionable. Some of the limitations are related to the fact that
many symptoms of depression are not measurable in preclinicalmodels; they are stressor-based and although there is evidence for a
link between depression and stress, this does not always follow. In
addition, they respond to the acute antidepressant treatment (Cryan
et al., 2002; Cryan and Slattery, 2007). In spite of these limitations,
these tests are useful for studying the mechanisms underlying the
antidepressant-like effects of several compounds.
We investigated the participation of NMDA receptors and L-arginine–
NO–cGMP pathway in the antidepressant-like effect of duloxetine in the
FST. This testwas chosen considering that the effects of themodulation of
NMDA receptors and NOS–cGMP pathway on the antidepressant-like
behavior in this test are well known, as compared to the TST (Almeida
et al., 2006; Brocardo et al., 2008; Dhir and Kulkarni, 2007; Ghasemi et
al., 2009, 2010; Harkin et al., 1999, 2003, 2004; Kaster et al.,
2005a,2005b; Rosa et al., 2003). For this aim, oral administration of
duloxetine was selected because it is the most common route of admin-
istration for antidepressants in psychiatric patients. In this study, we
showed that the reduction of the immobility time elicited by duloxetine
in the FST was prevented by NMDA and D-serine, a coagonist at the
NMDA receptor. Similar to our results, the antidepressant-like effect of
lithium and escitalopram in the FST was prevented by the pre-
treatment with NMDA (Ghasemi et al., 2010; Zomkowski et al., 2010).
Moreover, it was shown that NMDA receptor NR2A subunit knockout
mice exhibit anxiolytic-like effects in elevated plus-maze, light–dark ex-
ploration, novel and familiar open ﬁeld tests and home cage locomotor
activity and antidepressant-like effects in the FST and TST in mice
(Boyce-Rustay and Holmes, 2006). In addition, antidepressants have
been reported to reduce binding, expression and function of NMDA re-
ceptors (Boyer et al., 1998; Szasz et al., 2007). An evidence of a direct ac-
tion of ﬂuoxetine and desipramine inhibiting NMDA-evoked currents in
rat cortical cell cultures was reported, suggesting that direct inhibition
of NMDA receptors may contribute to the clinical effects of antidepres-
sants (Szasz et al., 2007). Furthermore, Poleszak et al. (2007) have
Fig. 4. Effect of 7-nitroindazole (50 mg/kg, i.p.) or methylene blue (20 mg/kg, i.p.) in combination with a sub-effective dose of duloxetine (0.3 mg/kg, p.o.) in the FST (panels A and
C, respectively) and in the open-ﬁeld test (panels B and D, respectively). The effect of duloxetine administration (10 mg/kg, p.o., 1 h before decapitation) in the NOx levels in the
hippocampus and cerebral cortex is shown in panel E. Values are expressed as mean±SEM, n=6. *pb0.05, **pb0.01 compared with the vehicle-treated control group.
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the anti-immobility effect of NMDA receptor antagonists in the FST. The
antidepressant effects of ﬂuoxetine, imipramine and reboxetine were
also reversed by D-serine (Poleszak et al., 2011). Therefore, our results
are in linewith the literature data reinforcing the role of theNMDA recep-
tors in the mechanism of action of antidepressant agents and in the
pathophysiology of depression, since they clearly indicate that the
antidepressant-like effect of duloxetine is mediated through a blockade
of NMDA receptor. However, our behavioral results do not allow us to
conclude about the mechanism by which duloxetine interacts with the
NMDA receptor and further studies are necessary to better clarify this
issue.
The synergistic antidepressant-like effect observed when mice
were treated with the non-competitive NMDA receptor antagonist
MK-801 combined with duloxetine reinforces the assumption that
duloxetine exerts its antidepressant-like effect by blocking NMDA
receptor activation. It is known that MK-801 preferentially binds
to the activated NMDA receptor complex (Javitt and Zukin, 1989)
interacting with a site located within the NMDA channel pore. In
concordance with our results, a study recently demonstrated that
the combined treatment of sub-effective doses of paroxetine and
MK-801 exerted antidepressant-like effect in the FST in mice
(Ghasemi et al., 2009). Moreover, some studies have demonstrateda synergistic effect of NMDA receptor antagonists with antidepres-
sants and lithium in the FST (Ghasemi et al., 2010; Rogóz et al.,
2002). However, there are little data on the mechanisms by which
NMDA antagonists enhance the effects of antidepressants in the FST.
A microdialysis study has demonstrated that acute administration of
noneffective doses of the NMDA antagonist amantadine combined
with noneffective doses of several antidepressants (paroxetine,
reboxetine, budipine and clomipramine) increases the cortical release
of 5-HT in freely moving rats (Owen and Whitton, 2005). Hence, we
cannot rule out the possibility that the antidepressant-like effects
elicited by treatment of mice with sub-effective doses of duloxetine
and NMDA antagonists may be due to their effects on the central
5-HT release.
The L-arginine–NO–cGMP pathway has been implicated in the
pathogenesis of depression (Kaster et al., 2005a, 2005b; Mantovani
et al., 2003). NO plays a signiﬁcant role in the central nervous system
and pharmacological manipulation of the NO pathway may constitute
a novel therapeutic approach for the treatment of depression (Harkin
et al., 2003, 2004). In this study, we showed that the reduction of im-
mobility time elicited by duloxetine in the FST was reversed by
pre-treatment of mice with L-arginine (NOS substrate) or SNAP, an
NO donor. Similarly to our results, the antidepressant-like effects of
imipramine, escitalopram, paroxetine and venlafaxine were also
Fig. 5. Effect of ODQ (30 pmol/site i.c.v.) in combination with a sub-effective dose of duloxetine (0.3 mg/kg, p.o.) in the FST (panel A) and in the open-ﬁeld test (panel B). Effect of
the pre-treatment of mice with sildenaﬁl (5 mg/kg, i.p.) on the anti-immobility effect of duloxetine (10 mg/kg, p.o.) in the FST (A) and on the number of crossings in the open-ﬁeld
test (B). Values are expressed as mean±SEM, n=6. **pb0.01 compared with the vehicle-treated control group; #pb0.01 compared with the same group pre-treated with vehicle.
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Ghasemi et al., 2009; Harkin et al., 2004; Zomkowski et al., 2010). In
previous studies, our group demonstrated that L-arginine and SNAP
reversed the antidepressant-like effects of putative antidepressant
agents such as zinc chloride (Rosa et al., 2003), adenosine (Kaster et
al., 2005b), memantine (Almeida et al., 2006), folic acid (Brocardo
et al., 2008) and ascorbic acid (Moretti et al., 2011). Therefore, a
great amount of literature data points to a signiﬁcant role of nitrergic
system in the mechanism of action of antidepressant agents. Corrob-
orating this notion, our results indicate that the effect of duloxetine
may be dependent on the inhibition of NO synthesis. Further
reinforcing this assumption, in this study, the pre-treatment of mice
with a sub-effective dose of 7-nitroindazole (a speciﬁc neuronal
NOS inhibitor), methylene blue (direct inhibitor of both NOS and
sGC) or ODQ (a speciﬁc inhibitor of sGC) produced a synergistic
antidepressant-like effect with duloxetine. Corroborating these re-
sults, duloxetine treatment was able to decrease NOx levels in the
hippocampus and cerebral cortex. Together this set of results suggests
that the inhibition of NO synthesis is implicated in the anti-
immobility effect of duloxetine in the FST and is in accordance with
the fact that NOS inhibitors exert antidepressant-like effect in animal
models of depression (Eroglu and Caglayan, 1997; Volke et al., 2003;
Yildiz et al., 2000). In addition, in line with our results, studies have
demonstrated that 7-nitroindazole potentiated the antidepressant-
like effect of venlafaxine (Dhir and Kulkarni, 2007), imipramine and
ﬂuoxetine (Harkin et al., 2004) in the FST. Similarly to our results, a
study showed that methylene blue potentiated the antidepressant-
like effect of venlafaxine in the FST (Dhir and Kulkarni, 2007). More-
over, it has been reported that the antidepressant-like effect
produced by ODQ in the FST in rats was reversed by pre-treatment
with L-arginine (Heiberg et al., 2002). In line with our results, ODQ
potentiated the antidepressant-like effects of lithium (Ghasemi et
al., 2008), adenosine (Kaster et al., 2005b) and memantine in themouse FST (Almeida et al., 2006). These results reinforce our hy-
pothesis that the anti-immobility effect of duloxetine in the FST is
dependent on the decrease in NO synthesis and also that it may be
mediated through the reduction of cGMP, likely as a consequence
of the reduction of NO synthesis. Noteworthy, a study reported
that L-arginine was able to partially prevent the inhibition of genital
vascular responses induced by duloxetine in rabbits, reinforcing the
notion that this antidepressant may act on NOS system (Angulo et
al., 2004). Although the present study does not allow us to know
exactly the mechanism responsible for the observed behavioral
effects, one possibility is that the effects are indirectly dependent
on an increase in the release of 5-HT. It is interesting to note that
the effects of NOS inhibitors in the FST are reported to be dependent
on endogenous 5-HT, since the depletion of 5-HT caused by the
treatment of rats with PCPA prevented the effects of NOS inhibitors
in the FST (Harkin et al., 2003). Furthermore, some studies have
demonstrated that inhibition of NOS can modulate the release of
central 5-HT (Kiss, 2000; Smith and Whitton, 2000; Wegener et
al., 2000).
Of note, we also showed that the pre-treatment of mice with sil-
denaﬁl (selective type 5 phosphodiesterase inhibitor) prevented the
antidepressant-like effect of duloxetine in the FST. Sildenaﬁl increases
the cGMP level in target tissues (Beavo, 1995) and was previously
reported to reverse the anti-immobility effect of ODQ in the mouse
FST (Kaster et al., 2005b). Our results are somewhat in accordance
with the literature data that showed that the reduction in the immo-
bility time elicited by the antidepressants venlafaxine (Dhir and
Kulkarni, 2007) and escitalopram (Zomkowski et al., 2010) was also
prevented by the pre-treatment with sildenaﬁl. This ﬁnding reported
here reinforces the notion that duloxetine exerts its effect in the FST
by decreasing cGMP levels.
In conclusion, our study demonstrated that duloxetine exerts an
antidepressant-like effect in the FST in mice when administered
416 A.D.E. Zomkowski et al. / Pharmacology, Biochemistry and Behavior 103 (2012) 408–417intraperitoneally and orally, conﬁrming the results obtained previ-
ously (Ciulla et al., 2007; Rénéric and Lucki, 1998) in the FST in rats.
In addition, its antidepressant-like effect also was shown in the TST
in mouse. Moreover, our results signiﬁcantly extend literature data
by indicating for the ﬁrst time the involvement of the NMDA recep-
tors and L-arginine–NO–cGMP pathway in the antidepressant-like ac-
tion of duloxetine in the FST. The acute duloxetine treatment also
decreased hippocampal and cerebrocortical NOx levels. It supports
the notion that the blockade of NMDA receptor, with the consequent
inhibition of NO and cGMP production may be critical to the antide-
pressant action of duloxetine and further reinforces the role of
NMDA receptors and L-arginine–NO–cGMP pathway, besides the
monoaminergic systems, in the mechanism of action of current pre-
scribed antidepressant agents.
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